Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated Traditional Chinese Medicine maintenance therapy versus single-agent chemotherapy in advanced non-small-cell lung cancer
ChiCTR-TRC-10001017Phase 4Completed
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Jul 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cinobufacini, compound kushen injection, pemetrexed, docetaxel and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Longhua Hospital Shanghai University of Traditional Chinese Medicine. Primary endpoints: 1-year survival rate, overall survival and 2 more. Started Jul 2009; status: completed.
02
Drugs
cinobufacinicompound kushen injectionpemetrexeddocetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-10001017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001017.